The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Blood fibrinogen as a biomarker of chronic obstructive pulmonary disease: Table 1
Open accessAbstract
BACKGROUND: Chronic obstructive pulmonary disease (COPD) is a multicomponent condition that is characterised by airflow obstruction that is not fully reversible and is a major global cause of morbidity and mortality. The most widely used marker of disease severity and progression is FEV1. However, FEV1 correlates poorly with both symptoms and other measures of disease progression and thus there is an urgent need for other biological markers to better characterise individuals with COPD. Fibrinogen is an acute phase plasma protein that has emerged as a promising biomarker in COPD. Here we review the current clinical evidence linking fibrinogen with COPD and its associated co-morbidities and discuss its potential utility as a biomarker. METHODS: Searches for appropriate studies were undertaken on PubMed using search terms fibrinogen, COPD, emphysema, chronic bronchitis, FEV1, cardiovascular disease, exacerbation and mortality. RESULTS: There is strong evidence of an association between fibrinogen and the presence of COPD, the presence and frequency of exacerbations and with mortality. Fibrinogen is associated with disease severity but does not predict lung function decline, a measure used as a surrogate for disease activity. The role of fibrinogen in identifying inflammatory co morbidities, particularly cardiovascular disease, remains unclear. Fibrinogen is reduced by p38 mitogen-activated protein kinase inhibitors in individuals with stable disease and by oral corticosteroids during exacerbations. CONCLUSIONS: Fibrinogen is likely to be a useful biomarker to stratify individuals with COPD into those with a high or low risk of future exacerbations and may identify those with a higher risk of mortality.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Vestbo, J., Hurd, S. S., Agustí, A. G., Jones, P. W., Vogelmeier, C., Anzueto, A., Barnes, P. J., Fabbri, L. M., Martinez, F. J., Nishimura, M., et al. (2013) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201204-0596pp · Cited by 15,983
Acute-Phase Proteins and Other Systemic Responses to Inflammation
Gabay, C., & Kushner, I. (1999) · New England Journal of Medicine · doi:10.1056/nejm199902113400607 · Cited by 6,734
Rabe, K. F., Hurd, S., Anzueto, A., Barnes, P. J., Buist, S. A., Calverley, P., Fukuchi, Y., Jenkins, C., Rodriguez-Roisin, R., van Weel, C., et al. (2007) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200703-456so · Cited by 4,925
Physical Activity and Reduced Risk of Cardiovascular Events: Potential Mediating Mechanisms
Mora, S., Cook, N., Buring, J. E., Ridker, P. M., & Lee, I.-M. (2007) · Circulation · doi:10.1161/circulationaha.107.729939 · Cited by 1,000
Emerging role of MAP kinase pathways as therapeutic targets in COPD
Mercer, B. A., & D'Armiento, J. M. (2006) · International Journal of COPD · doi:10.2147/copd.2006.1.2.137 · Cited by 118
Cited by
Broza, Y. Y., Zhou, X., Yuan, M., Qu, D., Zheng, Y., Vishinkin, R., Khatib, M., Wu, W., & Haick, H. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.9b00437 · Cited by 461
Ritchie, A. I., & Wedzicha, J. A. (2020) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2020.06.007 · Cited by 402
Metadata
- Authors
- Duvoix, A., Dickens, J., Haq, I., Mannino, D., Miller, B., Tal-Singer, R., & Lomas, D. A.
- Venue
- Thorax
- Publisher
- BMJ
- Published
- 2012-06-28
- Volume
- 68
- Issue
- 7
- Pages
- 670-676
- ISSN
- 0040-6376 (ISSN-L)
- 1468-3296
- OpenAlex
- W2147495597
- Cited by
- 214
- References
- 5
- FWCI
- 13.75
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Blood fibrinogen as a biomarker of chronic obstructive pulmonary disease: Table 1. https://app.cochat.ai/papers/10.1136/thoraxjnl-2012-201871
- The paper
- Duvoix, A., Dickens, J., Haq, I., Mannino, D., Miller, B., Tal-Singer, R., & Lomas, D. A. (2013). Blood fibrinogen as a biomarker of chronic obstructive pulmonary disease: Table 1. Thorax. https://doi.org/10.1136/thoraxjnl-2012-201871
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.